Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study

Breast cancer cell-derived soluble CD44 promotes tumor progression by triggering macrophage IL-1β production

(2020) Jeong-Hoon Jang et al.   CANCER RESEARCH

Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis

(2019) Luigi Cavanna et al.   Oncotarget

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

(2019) J Mazières et al.   ANNALS OF ONCOLOGY

Tumor mutational burden quantification from targeted gene panels: major advancements and challenges

(2019) Laura Fancello et al.   Journal for ImmunoTherapy of Cancer

Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab

(2019) Gaëlle Noé et al.   Cancers

The Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer

(2019) Taher Abu Hejleh et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC

(2018) MARIA BASSANELLI et al.   ANTICANCER RESEARCH

Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer

(2018) Masahiro Takeuchi et al.   IMMUNOLOGY LETTERS

Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab

(2018) Adrien Costantini et al.   OncoImmunology

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer

(2018) Muhammad Khan et al.   MEDICINE

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

(2018) David R. Gandara et al.   NATURE MEDICINE

Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis

(2018) Marcelo Bonomi et al.   Oncology Letters

Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients

(2017) Alicja Puszkiel et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

(2017) Matthew D Hellmann et al.   LANCET ONCOLOGY

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study

(2017) Elizabeth R Plimack et al.   LANCET ONCOLOGY

High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer

(2017) Yusuke Okuma et al.   LUNG CANCER

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

(2017) Aaron M. Goodman et al.   MOLECULAR CANCER THERAPEUTICS

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab

(2017) Shuguang Tan et al.   Nature Communications

Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer

(2017) Xinxin Zhu et al.   Oncotarget

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

(2017) Jun Zhou et al.   Cancer Immunology Research

Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer

(2017) Stephan Kruger et al.   OncoImmunology

PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis

(2017) Minghui Zhang et al.   Scientific Reports

Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges

(2016) Francesca Tartari et al.   CANCER TREATMENT REVIEWS

High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis

(2016) Fabian Finkelmeier et al.   EUROPEAN JOURNAL OF CANCER

N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins

(2016) Fabian Higel et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer

(2016) Naoki Takahashi et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2016) Scott Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR -mutated non-small cell lung cancer treated with erlotinib

(2016) Steffen Filskov Sorensen et al.   LUNG CANCER

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational signatures associated with tobacco smoking in human cancer

(2016) L. B. Alexandrov et al.   SCIENCE

Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy

(2016) Hyerim Ha et al.   Oncotarget

Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?

(2016) Yu-Ling Li et al.   Cancer Biology & Medicine

VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors

(2015) Thibault Voron et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer

(2015) Yaxiong Zhang et al.   MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs

(2015) Yanna Tang et al.   Oncotarget

Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics

(2015) Jie Zhang et al.   Thoracic Cancer

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

(2015) Luisa Carbognin et al.   PLoS One

Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma

(2014) Hye Chung et al.   Journal of Translational Medicine

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Circulating Programmed Death-1 as a Marker for Sustained High Hepatitis B Viral Load and Risk of Hepatocellular Carcinoma

(2014) Hsiang-Yun Cheng et al.   PLoS One

Reconstructed Adeno-Associated Virus with the Extracellular Domain of Murine PD-1 Induces Antitumor Immunity

(2013) Osama A.O. Elhag et al.   Asian Pacific Journal of Cancer Prevention

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

High circulating VEGF level predicts poor overall survival in lung cancer

(2013) Pingping Hu et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis

(2013) SR Greisen et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

The role of soluble CD40L in immunosuppression

(2013) Jeffrey Schlom et al.   OncoImmunology

Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role

(2012) J. Huang et al.   BLOOD

Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines

(2011) Yongjing Chen et al.   CYTOKINE

Soluble B7-H1: Differences in production between dendritic cells and T cells

(2011) Xavier Frigola et al.   IMMUNOLOGY LETTERS